A detailed history of Candriam S.C.A. transactions in Dr Reddys Laboratories LTD stock. As of the latest transaction made, Candriam S.C.A. holds 34,000 shares of RDY stock, worth $499,460. This represents 0.02% of its overall portfolio holdings.

Number of Shares
34,000
Previous 40,000 15.0%
Holding current value
$499,460
Previous $3.05 Million 11.36%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$75.41 - $84.21 $452,460 - $505,259
-6,000 Reduced 15.0%
34,000 $2.7 Million
Q2 2024

Aug 05, 2024

SELL
$68.26 - $76.19 $682,600 - $761,900
-10,000 Reduced 20.0%
40,000 $3.05 Million
Q1 2024

May 03, 2024

BUY
$67.36 - $77.59 $1.35 Million - $1.55 Million
20,000 Added 66.67%
50,000 $3.67 Million
Q4 2023

Feb 14, 2024

BUY
$64.27 - $69.9 $192,810 - $209,700
3,000 Added 11.11%
30,000 $2.09 Million
Q3 2023

Nov 13, 2023

BUY
$61.9 - $72.77 $309,500 - $363,850
5,000 Added 22.73%
27,000 $1.81 Million
Q2 2023

Aug 08, 2023

BUY
$53.34 - $63.11 $213,360 - $252,440
4,000 Added 22.22%
22,000 $1.39 Million
Q1 2023

May 12, 2023

BUY
$51.63 - $56.93 $206,520 - $227,720
4,000 Added 28.57%
18,000 $1.02 Million
Q4 2022

Feb 13, 2023

BUY
$51.15 - $57.45 $716,100 - $804,300
14,000 New
14,000 $724,000
Q3 2020

Oct 19, 2020

SELL
$51.39 - $72.41 $719,460 - $1.01 Million
-14,000 Closed
0 $0
Q2 2020

Jul 23, 2020

BUY
$39.55 - $54.65 $553,700 - $765,100
14,000 New
14,000 $742,000
Q1 2019

May 02, 2019

SELL
$35.77 - $40.57 $643,860 - $730,260
-18,000 Closed
0 $0
Q3 2018

Nov 07, 2018

BUY
$29.25 - $36.73 $526,500 - $661,140
18,000 New
18,000 $623,000

Others Institutions Holding RDY

About DR REDDYS LABORATORIES LTD


  • Ticker RDY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 166,028,992
  • Market Cap $2.44B
  • Description
  • Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-t...
More about RDY
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.